XML 23 R11.htm IDEA: XBRL DOCUMENT
v3.25.2

Divestiture | 9 Months Ended
--- | ---
Jul. 31, 2025
Discontinued Operations and Disposal Groups [Abstract] |
Mergers, Acquisitions and Dispositions Disclosures | Divestiture and related charges In the third quarter of 2025, we entered into a definitive agreement to sell select product lines in the medical contract manufacturing business within the MFS segment and determined that the criteria to be classified as held for sale were met. Therefore, these assets and liabilities have been presented as held for sale in the Consolidated Balance Sheet as of July 31, 2025. Assets and liabilities classified as held for sale are measured at the lower of carrying value or fair value less costs to sell. Before measuring the fair value less costs to sell of the disposal group as a whole, we first reviewed individual assets and liabilities to determine if any fair value adjustments were required and concluded no individual asset impairments were required. Then, based on the definitive agreement entered into by us and the buyer, we determined the fair value of the disposal group to be equal to the selling price, less costs to sell. Based on this review, we recorded a non-cash impairment charge of $4,726. The assets and liabilities of the disposal group classified as held for sale at July 31, 2025 were as follows:
| July 31, 2025 |  |
Receivables - net | $ | 4,650 |  |  |
Inventories - net | 5,602 |  |  |
Prepaid expenses and other current assets | 5,877 |  |  |
Property, plant and equipment - net | 13,988 |  |  |
Operating right of use lease assets | 3,627 |  |  |
Goodwill | 10,565 |  |  |
Impairment on carrying value | (4,726) |  |  |
Assets held for sale | $ | 39,583 |  |  |
Accounts payable | $ | 703 |  |  |
Accrued liabilities | 1,729 |  |  |
Operating lease liability | 3,685 |  |  |
Finance lease liability | 4,690 |  |  |
Liabilities held for sale | $ | 10,807 |  |  |
The pending sale of select product lines in the medical contract manufacturing business is subject to customary closing conditions and is expected to close no later than the fourth quarter of 2025. In the third quarter of 2025, as part of its exit of the medical contract manufacturing business, the Company also announced the planned closure of its remaining medical contract manufacturing facility and recognized a charge of $7,485, principally associated with the write-off of leasehold improvements and the write-down of an operating right of use lease asset.

X
- References No definition available. + Details
Name: | us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent + Details
Name: | us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration